Blog

Karen Knudsen: We are launching a lung cancer screening program

Photo taken from: American Cancer Society/LinkedIn

Nov 18, 2023, 01:13

Karen Knudsen: We are launching a lung cancer screening program

Karen Knudsen, shared a post by American Cancer Society, on LinkedIn adding the following:

“I’m proud to unveil the American Cancer Society‘s latest collaboration with Color Health.

Too many people continue to die from lung cancer — we have to do better. Annual screening is vital to reducing lung cancer deaths, but as it stands now, only 6% of eligible Americans get screened.

Today, we are launching a lung cancer screening program. Color is taking care of everything from ordering the test, to finding a local radiology clinic, and even booking your appointment. All you have to do is go in for a painless, 10-minute scan!”

Quoting American Cancer Society:

“Lung cancer is the second most frequently diagnosed cancer and the leading cause of cancer death in the United States. We’re working with Color Health to provide a convenient, free screening access program for the almost 20 million Americans who are now eligible for lung cancer screenings under the updated ACS guideline.”

For details click here.
Source: Karen Knudsen/LinkedIn and American Cancer Society/LinkedIn

Karen E. Knudsen is the CEO of the American Cancer Society (ACS) and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health. She also served as president for the Association of American Cancer Institutes (AACI), representing the 102 leading cancer centers in North America, and on the board of directors of the American Association for Cancer Research (AACR). Dr. Knudsen currently holds leadership roles with some of the most important cancer entities in the United States. She serves on the board of advisors for the National Cancer Institute and on 12 external advisory boards for NCI-designated cancer centers. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.